Cargando…

Vaccine hesitancy in the French population in 2016, and its association with vaccine uptake and perceived vaccine risk–benefit balance

Vaccine hesitancy (VH) is prominent in France. Objectives: This study aimed to estimate the prevalence and socio-demographic correlates of VH in sub-groups of the French population and to investigate the association of VH with both vaccine uptake and perceived risk–benefit balance (RBB) for four vac...

Descripción completa

Detalles Bibliográficos
Autores principales: Rey, Dominique, Fressard, Lisa, Cortaredona, Sébastien, Bocquier, Aurélie, Gautier, Arnaud, Peretti-Watel, Patrick, Verger, Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930729/
https://www.ncbi.nlm.nih.gov/pubmed/29717693
http://dx.doi.org/10.2807/1560-7917.ES.2018.23.17.17-00816
_version_ 1783319525258690560
author Rey, Dominique
Fressard, Lisa
Cortaredona, Sébastien
Bocquier, Aurélie
Gautier, Arnaud
Peretti-Watel, Patrick
Verger, Pierre
author_facet Rey, Dominique
Fressard, Lisa
Cortaredona, Sébastien
Bocquier, Aurélie
Gautier, Arnaud
Peretti-Watel, Patrick
Verger, Pierre
author_sort Rey, Dominique
collection PubMed
description Vaccine hesitancy (VH) is prominent in France. Objectives: This study aimed to estimate the prevalence and socio-demographic correlates of VH in sub-groups of the French population and to investigate the association of VH with both vaccine uptake and perceived risk–benefit balance (RBB) for four vaccines. Methods: During the 2016 Health Barometer – a national cross-sectional telephone survey in a representative sample of the French population – parents of 1–15 year-old children, parents of 11–15 year-old girls and elderly people aged 65–75 years were asked about VH (using three questions adapted from the World Health Organization definition), vaccine uptake and perceived RBB for measles and hepatitis B (children’s parents), human papillomavirus (girls’ parents) and seasonal influenza (elderly people) vaccines. Results: A total of 3,938 parents including 959 girls' parents – and 2,418 elderly people were interviewed. VH prevalence estimates were 46% (95% confidence interval (CI): 44–48) among parents, 48% (95%CI: 45–51) among girls’ parents and 35% (95% CI: 33–36) among elderly people, with higher estimates associated with high education level, children’s age (10–15 years), and, for the elderly, poor perception of health status. VH was associated with uncertainty about and/or an unfavourable perception of vaccines’ RBB for the four vaccines and with lower self-reported vaccine uptake, except for human papillomavirus vaccine in girls. Results were confirmed by multivariable analysis. Conclusion: Further research is needed to study the association between VH and vaccine uptake for other vaccines, and to design and validate measurement tools to monitor VH over time.
format Online
Article
Text
id pubmed-5930729
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher European Centre for Disease Prevention and Control (ECDC)
record_format MEDLINE/PubMed
spelling pubmed-59307292018-05-09 Vaccine hesitancy in the French population in 2016, and its association with vaccine uptake and perceived vaccine risk–benefit balance Rey, Dominique Fressard, Lisa Cortaredona, Sébastien Bocquier, Aurélie Gautier, Arnaud Peretti-Watel, Patrick Verger, Pierre Euro Surveill Research Article Vaccine hesitancy (VH) is prominent in France. Objectives: This study aimed to estimate the prevalence and socio-demographic correlates of VH in sub-groups of the French population and to investigate the association of VH with both vaccine uptake and perceived risk–benefit balance (RBB) for four vaccines. Methods: During the 2016 Health Barometer – a national cross-sectional telephone survey in a representative sample of the French population – parents of 1–15 year-old children, parents of 11–15 year-old girls and elderly people aged 65–75 years were asked about VH (using three questions adapted from the World Health Organization definition), vaccine uptake and perceived RBB for measles and hepatitis B (children’s parents), human papillomavirus (girls’ parents) and seasonal influenza (elderly people) vaccines. Results: A total of 3,938 parents including 959 girls' parents – and 2,418 elderly people were interviewed. VH prevalence estimates were 46% (95% confidence interval (CI): 44–48) among parents, 48% (95%CI: 45–51) among girls’ parents and 35% (95% CI: 33–36) among elderly people, with higher estimates associated with high education level, children’s age (10–15 years), and, for the elderly, poor perception of health status. VH was associated with uncertainty about and/or an unfavourable perception of vaccines’ RBB for the four vaccines and with lower self-reported vaccine uptake, except for human papillomavirus vaccine in girls. Results were confirmed by multivariable analysis. Conclusion: Further research is needed to study the association between VH and vaccine uptake for other vaccines, and to design and validate measurement tools to monitor VH over time. European Centre for Disease Prevention and Control (ECDC) 2018-04-26 /pmc/articles/PMC5930729/ /pubmed/29717693 http://dx.doi.org/10.2807/1560-7917.ES.2018.23.17.17-00816 Text en This article is copyright of The Authors, 2018. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.
spellingShingle Research Article
Rey, Dominique
Fressard, Lisa
Cortaredona, Sébastien
Bocquier, Aurélie
Gautier, Arnaud
Peretti-Watel, Patrick
Verger, Pierre
Vaccine hesitancy in the French population in 2016, and its association with vaccine uptake and perceived vaccine risk–benefit balance
title Vaccine hesitancy in the French population in 2016, and its association with vaccine uptake and perceived vaccine risk–benefit balance
title_full Vaccine hesitancy in the French population in 2016, and its association with vaccine uptake and perceived vaccine risk–benefit balance
title_fullStr Vaccine hesitancy in the French population in 2016, and its association with vaccine uptake and perceived vaccine risk–benefit balance
title_full_unstemmed Vaccine hesitancy in the French population in 2016, and its association with vaccine uptake and perceived vaccine risk–benefit balance
title_short Vaccine hesitancy in the French population in 2016, and its association with vaccine uptake and perceived vaccine risk–benefit balance
title_sort vaccine hesitancy in the french population in 2016, and its association with vaccine uptake and perceived vaccine risk–benefit balance
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930729/
https://www.ncbi.nlm.nih.gov/pubmed/29717693
http://dx.doi.org/10.2807/1560-7917.ES.2018.23.17.17-00816
work_keys_str_mv AT reydominique vaccinehesitancyinthefrenchpopulationin2016anditsassociationwithvaccineuptakeandperceivedvaccineriskbenefitbalance
AT fressardlisa vaccinehesitancyinthefrenchpopulationin2016anditsassociationwithvaccineuptakeandperceivedvaccineriskbenefitbalance
AT cortaredonasebastien vaccinehesitancyinthefrenchpopulationin2016anditsassociationwithvaccineuptakeandperceivedvaccineriskbenefitbalance
AT bocquieraurelie vaccinehesitancyinthefrenchpopulationin2016anditsassociationwithvaccineuptakeandperceivedvaccineriskbenefitbalance
AT gautierarnaud vaccinehesitancyinthefrenchpopulationin2016anditsassociationwithvaccineuptakeandperceivedvaccineriskbenefitbalance
AT perettiwatelpatrick vaccinehesitancyinthefrenchpopulationin2016anditsassociationwithvaccineuptakeandperceivedvaccineriskbenefitbalance
AT vergerpierre vaccinehesitancyinthefrenchpopulationin2016anditsassociationwithvaccineuptakeandperceivedvaccineriskbenefitbalance
AT vaccinehesitancyinthefrenchpopulationin2016anditsassociationwithvaccineuptakeandperceivedvaccineriskbenefitbalance